Icotrokinra Retains Efficacy in Psoriasis Patients on GLP-1 Therapy
Clinical Advisor reports a post-hoc pooled analysis of phase 3 ICONIC data, presented at FC26, on oral icotrokinra for moderate to severe plaque psoriasis. Only 31 of 2187 patients were exposed to GLP-1 medications; their week-16 skin clearance, safety and drug levels appeared similar to non-users. Researchers noted small samples, reduced statistical power and missing GLP-1 dosing details limit interpretation.
Why it matters: Relevant to adults with moderate to severe plaque psoriasis who use GLP-1 medications, and the dermatology and weight-management clinicians who treat them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to clinicaladvisor.com. October 9, 2026.
